PMID- 37559541
OWN - NLM
STAT- Publisher
LR  - 20230810
IS  - 1875-5402 (Electronic)
IS  - 1386-2073 (Linking)
DP  - 2023 Aug 8
TI  - Anti-angiogenic agents combined with immunotherapy for advanced non-small cell 
      lung cancer: a systematic review and meta-analysis.
LID - 10.2174/1386207326666230808112656 [doi]
AB  - BACKGROUND: Anti-angiogenic agents could enhance tumor immunity response, and 
      anti-angiogenesis plus immunotherapy has become a novel treatment option for 
      advanced non-small cell lung cancer (NSCLC). The efficacy of this combination 
      therapy remains controversial and obscure. AIM: We conducted a meta-analysis to 
      evaluate the clinical efficacy and safety of this therapeutic strategy in 
      patients with advanced NSCLC and provide more guidance for treating NSCLC 
      clinically. METHODS: A systematic literature search was performed in PubMed, 
      Embase, Web of Science, CNKI, and Wanfang databases to identify relevant studies 
      published up to December 2021. The primary endpoint was the objective response 
      rate (ORR). Second endpoints were progression-free survival (PFS), overall 
      survival (OS), and grade >/=3 AEs adverse events (AEs). The sensitivity analysis 
      was conducted to confirm the stability of the results. STATA 15.0 was utilized 
      for all pooled analyses. RESULTS: Eleven studies were eventually included in the 
      meta-analysis, involving 533 patients with advanced NSCLC. The pooled ORR rate 
      was 27% (95% CI 18% to 35%; I2 =84.2%; p<0.001), while the pooled median PFS and 
      OS was 5.84 months (95% CI 4.66 to 7.03 months; I2=78.4%; p<0.001) and 14.20 
      months (95% CI 11.08 to 17.32 months; I2=82.2%; p=0.001), respectively. Most 
      common grade >/=3 AEs included hypertension, hand-foot syndrome, diarrhea, adrenal 
      insufficiency, hyponatremia, proteinuria, rash, thrombocytopenia, and fatigue. 
      CONCLUSION: Anti-angiogenesis combined with immunotherapy demonstrated 
      satisfactory antitumor activity and an acceptable toxicity profile in patients 
      with advanced NSCLC. The pooled results of our meta-analysis provided further 
      evidence supporting the favorable efficacy and safety of this therapeutic 
      strategy.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Lin, Heng
AU  - Lin H
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Ma, Chenhui
AU  - Ma C
AD  - Department of Radiology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Zhong, Aihong
AU  - Zhong A
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Zang, Huanping
AU  - Zang H
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Chen, Wenxin
AU  - Chen W
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Li, Lixiu
AU  - Li L
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Le, Yuyin
AU  - Le Y
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
FAU - Xie, Qiang
AU  - Xie Q
AD  - Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, District Fuzhou, 
      Fujian, 350008, China.
LA  - eng
PT  - Meta-Analysis
DEP - 20230808
PL  - United Arab Emirates
TA  - Comb Chem High Throughput Screen
JT  - Combinatorial chemistry & high throughput screening
JID - 9810948
SB  - IM
OTO - NOTNLM
OT  - Anti-angiogenesis
OT  - Combination therapy
OT  - Immunotherapy
OT  - Meta-analysis
OT  - Non-small cell lung cancer (NSCLC)
EDAT- 2023/08/10 06:43
MHDA- 2023/08/10 06:43
CRDT- 2023/08/10 03:37
PHST- 2023/01/31 00:00 [received]
PHST- 2023/06/17 00:00 [revised]
PHST- 2023/07/03 00:00 [accepted]
PHST- 2023/08/10 06:43 [medline]
PHST- 2023/08/10 06:43 [pubmed]
PHST- 2023/08/10 03:37 [entrez]
AID - CCHTS-EPUB-133445 [pii]
AID - 10.2174/1386207326666230808112656 [doi]
PST - aheadofprint
SO  - Comb Chem High Throughput Screen. 2023 Aug 8. doi: 
      10.2174/1386207326666230808112656.